Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...